Bone response to intermittent parathyroid hormone is altered in mice null for β-arrestin2

Endocrinology

Volumn 146, Issue 4, 2005, Pages 1854-1862

  Ferrari, S L ^a   Pierroz, D D ^a   Glatt, V ^b   Goddard, D S ^b   Bianchi, E N ^a   Lin, F T ^c   Manen, D ^a   Bouxsein, M L ^b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ARRESTIN; BETA ARRESTIN 2; CYCLIC AMP; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MASS; BONE METABOLISM; BONE TURNOVER; CONTROLLED STUDY; CORTICAL BONE; MALE; MORPHOMETRICS; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; PRIORITY JOURNAL; TRABECULAR BONE;

ANIMALS; ARRESTINS; BONE AND BONES; BONE DENSITY; CALCIUM; CARRIER PROTEINS; GLYCOPROTEINS; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; OSTEOBLASTS; OSTEOPROTEGERIN; PARATHYROID HORMONE; PHOSPHATES; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 15444367508     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2004-1282     Document Type: Article

References (42)

1. Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster D, Cosman F 1997 Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350:550-555
2. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441
3. Qin L, Raggatt LJ, Partridge NC 2004 Parathyroid hormone: a double-edged sword for bone metabolism. Trends Endocrinol Metab 15:60-65
4. Hock JM, Gera I 1992 Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone. J Bone Miner Res 7:65-72
5. Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R 1993 Anabolic actions of parathyroid hormone on bone. Endocr Rev 14:690-709
6. Ma YL, Cain RL, Halladay DL, Yang X, Zeng Q, Miles RR, Chandrasekhar S, Martin TJ, Onyia JE 2001 Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 142:4047-4054
7. Locklin RM, Khosla S, Turner RT, Riggs BL 2003 Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone. J Cell Biochem 89:180-190
8. Aubin JE, Bonnelye E 2000 Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. Osteop Int 11:905-913
9. Goltzman D 1999 Interactions of PTH and PTHrP with the PTH/PTHrP receptor and with downstream signaling pathways: exceptions that provide the rules. J Bone Miner Res 14:173-177
10. Mannstadt M, Juppner H, Gardella TJ 1999 Receptors for PTH and PTHrP: their biological importance and functional properties. Am J Physiol 277:F665-F675
11. Fujita T, Meguro T, Fukuyama R, Nakamuta H, Koida M 2002 New signaling pathway for parathyroid hormone and cyclic AMP action on extracellular-regulated kinase and cell proliferation in bone cells. Checkpoint of modulation by cyclic AMP. J Biol Chem 277:22191-22200
12. Koh AJ, Beecher CA, Rosol TJ, McCauley LK 1999 3′,5′-Cyclic adenosine monophosphate activation in osteoblastic cells: effects on parathyroid hormone-1 receptors and osteoblastic differentiation in vitro. Endocrinology 140: 3154-3162
13. Ishizuya T, Yokose S, Hori M, Noda T, Suda T, Yoshiki S, Yamaguchi A 1997 Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells. J Clin Invest 99:2961-2970
14. Halladay DL, Miles RR, Thirunavukkarasu K, Chandrasekhar S, Martin TJ, Onyia JE 2001 Identification of signal transduction pathways and promoter sequences that mediate parathyroid hormone 1-38 inhibition of osteoprotegerin gene expression. J Cell Biochem 84:1-11
15. Hilliker S, Wergedal JE, Gruber HE, Bettica P, Baylink DJ 1996 Truncation of the amino terminus of PTH alters its anabolic activity on bone in vivo. Bone 19:469-477
16. Krupnick JG, Benovic JL 1998 The role of receptor kinases and arrestins in G protein-coupled receptor regulation. Annu Rev Pharmacol Toxicol 38:289-319
17. Luttrell LM, Lefkowitz RJ 2002 The role of β-arrestins in the termination and transduction of G-protein-coupled receptor signals. J Cell Sci 115:455-465
18. Ferrari SL, Behar V, Chorev M, Rosenblatt M, Bisello A 1999 Endocytosis of ligand-human parathyroid hormone receptor 1 complexes is protein kinase C-dependent and involves β-arrestin2. Real-time monitoring by fluorescence microscopy. J Biol Chem 274:29968-29975
19. Ferrari SL, Bisello A 2001 Cellular distribution of constitutively active mutant parathyroid hormone (PTH)/PTH-related protein receptors and regulation of cyclic adenosine 3′,5′-monophosphate signaling by β-arrestin2. Mol Endocrinol 15:149-163
20. Bisello A, Chorev M, Rosenblatt M, Monticelli L, Mierke DF, Ferrari SL 2002 Selective ligand-induced stabilization of active and desensitized parathyroid hormone type 1 receptor conformations. J Biol Chem 277:38524-38530
21. Perry SJ, Baillie GS, Kohout TA, McPhee I, Magiera MM, Ang KL, Miller WE, McLean AJ, Conti M, Houslay MD, Lefkowitz RJ 2002 Targeting of cyclic AMP degradation to β2-adrenergic receptors by β-arrestins. Science 298:834-836
22. Castro M, Dicker F, Vilardaga JP, Krasel C, Bernhardt M, Lohse MJ 2002 Dual regulation of the parathyroid hormone (PTH)/PTH-related peptide receptor signaling by protein kinase C and β-arrestins. Endocrinology 143:3854-3865
23. Lefkowitz RJ 1998 G protein-coupled receptors. III. New roles for receptor kinases and β-arrestins in receptor signaling and desensitization. J Biol Chem 273:18677-18680
24. Luttrell LM, Roudabush FL, Choy EW, Miller WE, Field ME, Pierce KL, Lefkowitz RJ 2001 Activation and targeting of extracellular signal-regulated kinases by β-arrestin scaffolds. Proc Natl Acad Sci USA 98:2449-2454
25. Bohn LM, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MG, Lin FT 1999 Enhanced morphine analgesia in mice lacking β-arrestin 2. Science 286:2495-2498
26. Conner DA, Mathier MA, Mortensen RM, Christe M, Vatner SF, Seidman CE, Seidman JG 1997 β-Arrestin1 knockout mice appear normal but demonstrate altered cardiac responses to β-adrenergic stimulation. Circ Res 81:1021-1026
27. Bohn LM, Gainetdinov RR, Lin FT, Lefkowitz RJ, Caron MG 2000 μ-Opioid receptor desensitization by β-arrestin2 determines morphine tolerance but not dependence. Nature 408:720-723
28. Walker JK, Fong AM, Lawson BL, Savov JD, Patel DD, Schwartz DA, Lefkowitz RJ 2003 β-Arrestin2 regulates the development of allergic asthma. J Clin Invest 112:566-574
29. Bouxsein ML, Rosen CJ, Turner CH, Ackert CL, Shultz KL, Donahue LR, Churchill G, Adamo ML, Powell DR, Turner RT, Muller R, Beamer WG 2002 Generation of a new congenic mouse strain to test the relationships among serum insulin-like growth factor I, bone mineral density, and skeletal morphology in vivo. J Bone Miner Res 17:570-579
30. Hildebrand T, Laib A, Muller R, Dequeker J, Ruegsegger P 1999 Direct three-dimensional morphometric analysis of human cancellous bone: microstructural data from spine, femur, iliac crest, and calcaneus. J Bone Miner Res 14:1167-1174
31. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595-610
32. Chen P, Toribara T, Warner H 1956 Microdetermination of phosphorus. Anal Chem 28:1756-1758
33. Bliziotes M, Murtagh J, Wiren K 1996 β-Adrenergic receptor kinase-like activity and β-arrestin are expressed in osteoblastic cells. J Bone Miner Res 11:820-826
34. Yu XP, Chandrasekhar S 1997 Parathyroid hormone (PTH 1-34) regulation of rat osteocalcin gene transcription. Endocrinology 138:3085-3092
35. McCarthy TL, Centrella M, Canalis E 1990 Cyclic AMP induces insulin-like growth factor I synthesis in osteoblast-enriched cultures. J Biol Chem 265: 15353-15356
36. Kanzawa M, Sugimoto T, Kanatani M, Chihara K 2000 Involvement of osteoprotegerin/osteoclastogenesis inhibitory factor in the stimulation of osteoclast formation by parathyroid hormone in mouse bone cells. Eur J Endocrinol 142:661-664
37. Dobnig H, Turner RT 1997 The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology 138:4607-4612
38. Lotinun S, Sibonga JD, Turner RT 2002 Differential effects of intermittent and continuous administration of parathyroid hormone on bone histomorphometry and gene expression. Endocrine 17:29-36
39. Kneissel M, Boyde A, Gasser JA 2001 Bone tissue and its mineralization in aged estrogen-depleted rats after long-term intermittent treatment with parathyroid hormone (PTH) analog SDZ PTS 893 or human PTH(1-34). Bone 28:237-250
40. Calvi BR, Spradling AC 2001 The nuclear location and chromatin organization of active chorion amplification origins. Chromosoma 110:159-172
41. Pierroz DD, Bouxsein ML, Glatt V, Rizzoli R, Ferrari SL 2004 Arrestins regulate bone remodeling induced by ovariectomy and intermittent PTH treatment. Calcif Tissue Int 74:341
42. Spurney RF, Flannery PJ, Garner SC, Athirakul K, Liu S, Guilak F, Quarles LD 2002 Anabolic effects of a G protein-coupled receptor kinase inhibitor expressed in osteoblasts. J Clin Invest 109:1361-1371